UK markets closed
NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,439.91 -36.01 (-0.19%) CRUDE OIL
78.48 +0.37 (+0.47%) GOLD FUTURES
2,315.60 +7.00 (+0.30%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
51,112.29 +661.37 (+1.31%)
Tyra Biosciences, Inc. (TYRA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 18.53 |
| Open | 19.07 |
| Bid | 17.77 x 100 |
| Ask | 17.88 x 200 |
| Day's range | 17.43 - 19.24 |
| 52-week range | 10.38 - 20.67 |
| Volume | |
| Avg. volume | 129,705 |
| Market cap | 937.552M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.60 |
- GuruFocus.com
Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress
Recent Financial Highlights Indicate Strong Cash Position and Advancements in Clinical Studies
PR NewswireTyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.
GuruFocus.comInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares
Tyra Biosciences Inc (NASDAQ:TYRA), a company focused on developing precision medicine for patients with cancer, has reported an insider sell according to a recent SEC filing.
© 2024 Yahoo. All rights reserved.